GRF Stock Overview
Operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Grifols, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.49 |
| 52 Week High | €11.35 |
| 52 Week Low | €7.32 |
| Beta | 0.93 |
| 1 Month Change | 13.56% |
| 3 Month Change | -10.60% |
| 1 Year Change | 3.26% |
| 3 Year Change | -49.62% |
| 5 Year Change | -65.06% |
| Change since IPO | 261.68% |
Recent News & Updates
Shareholder Returns
| GRF | ES Biotechs | ES Market | |
|---|---|---|---|
| 7D | 1.6% | 0.7% | -1.0% |
| 1Y | 3.3% | 2.3% | 19.5% |
Return vs Industry: GRF matched the Spanish Biotechs industry which returned 3% over the past year.
Return vs Market: GRF underperformed the Spanish Market which returned 21.1% over the past year.
Price Volatility
| GRF volatility | |
|---|---|
| GRF Average Weekly Movement | 6.1% |
| Biotechs Industry Average Movement | 8.6% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in ES Market | 6.8% |
| 10% least volatile stocks in ES Market | 0.5% |
Stable Share Price: GRF's share price has been volatile over the past 3 months compared to the Spanish market.
Volatility Over Time: GRF's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Spanish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1909 | 23,800 | Nacho Abia Buenache | www.grifols.com |
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It also markets diagnostic testing equipment, reagents, and other equipment; offers biological products and manufacturing services; and manufactures and sells plasma to third parties.
Grifols, S.A. Fundamentals Summary
| GRF fundamental statistics | |
|---|---|
| Market cap | €5.90b |
| Earnings (TTM) | €195.23m |
| Revenue (TTM) | €7.37b |
Is GRF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GRF income statement (TTM) | |
|---|---|
| Revenue | €7.37b |
| Cost of Revenue | €4.47b |
| Gross Profit | €2.90b |
| Other Expenses | €2.71b |
| Earnings | €195.23m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.29 |
| Gross Margin | 39.39% |
| Net Profit Margin | 2.65% |
| Debt/Equity Ratio | 121.1% |
How did GRF perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 00:32 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Grifols, S.A. is covered by 42 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kamla Singh | AlphaValue |
| Guilherme Sampaio | Banco BPI, S.A. |
| null null | Banco de Sabadell. S.A. |